12
ALL1
Aexon Labs1
Bioprojet Pharma1
Eagle Pharmaceuticals2
Enalare Therapeutics1
F. Hoffmann-La Roche4
NLS Pharmaceutics1
Orexia Therapeutics1
Tris Pharma IncYear
12
ALL1
20254
20242
20233
20222
2021DEALS // DEV.
12
ALL5
Deals7
DevelopmentsCountry
10
ALL1
FRANCE3
SWITZERLAND5
U.S.A1
UNITED KINGDOM12
ALL2
Aexon Labs1
Centessa Pharmaceuticals1
Enalare Therapeutics1
Harmony Biosciences1
NLS Pharmaceutics1
National Institutes of Health4
Not Applicable1
PsychoGenicsTherapeutic Area
12
ALL12
SleepStudy Phase
12
ALL12
PreclinicalDeal Type
6
ALL1
Agreement1
Inapplicable3
Licensing Agreement1
MergerProduct Type
12
ALL1
Other Small Molecule8
Small molecule3
UndisclosedDosage Form
4
ALL1
Inhalation1
Injectable/Injection1
Intraperitoneal Injection1
OralLead Product
12
ALL2
AEX-22
AEX-413
ENA-0011
RO71179971
Sodium Oxybate1
TPM-11162
UndisclosedTarget
5
ALL1
GABA B receptor1
OX1/2 receptor3
Potassium ion channelLead Product(s) : AEX-2
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Aexon Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
NLS Announces Preclinical Data for AEX-2 Dual Orexin Agonist
Details : AEX-2 is a potential first-in-class non-sulfonamide dual orexin receptor agonist (DOXA), which is being evaluated for narcolepsy and related neurological disorders.
Product Name : AEX-2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Aexon Labs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AEX-41
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NLS Reports Preclinical Data for Dual Orexin Agonists in Narcolepsy Treatment
Details : AEX-41 is a first-in-class non-sulfonamide DOXAs, are designed to target both OX1R/OX2R while inhibiting cathepsins, which play significant role in narcolepsy and other neurological disorders.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 03, 2024
Lead Product(s) : AEX-41
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AEX-41
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NLS Showcases Preclinical Non-Sulfonamide Dual Orexin Agonists for Narcolepsy
Details : AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both OX1R and OX2R to address the unmet needs in narcolepsy and related neurological disorders.
Product Name : AEX-41
Product Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2024
Lead Product(s) : AEX-41
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mazindol
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NLS Pharmaceutics Reports Positive KO-874 Study on Mazindol for Narcoleptic-like Model
Details : The Company's lead candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of orexin-B-saporin induced narcolepsy.
Product Name : Quilience
Product Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2024
Lead Product(s) : Mazindol
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TPM-1116
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Harmony Enters Agreement to Develop Oral Orexin-2 Agonist TPM-1116
Details : Through the Licensing Agreement, Bioprojet will develop, manufacture, and commercialize TPM-1116, a selective oral orexin-2 receptor agonist for narcolepsy and other sleep/wake disorders.
Product Name : TPM-1116
Product Type : Small molecule
Upfront Cash : $25.5 million
April 11, 2024
Lead Product(s) : TPM-1116
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Harmony Biosciences
Deal Size : $393.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NLS Pharmaceutics Secures Exclusive Global License for Dual Orexin Agonist Platform
Details : The agreement grants NLS global rights to next-gen oral OX1R/OX2R agonists, including AEX-2, tailored for narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies.
Product Name : AEX-2
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : RO7117997
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : PsychoGenics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Roche obtains global development, manufacturing, and commercialization rights to RO7117997, an IND-ready ENT1 inhibitor discovered using the PsychoGenics’ AI-enabled phenotypic screening platforms.
Product Name : RO7117997
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 01, 2023
Lead Product(s) : RO7117997
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : PsychoGenics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Aexon Labs
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, NLS may acquire development and commercialization rights to Aexon Labs' dual orexin receptor agonists platform for the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Aexon Labs
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ENA-001
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : Enalare Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
Product Name : ENA-001
Product Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2022
Lead Product(s) : ENA-001
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : Enalare Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ENA-001
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid b...
Product Name : ENA-001
Product Type : Small molecule
Upfront Cash : Not Applicable
October 03, 2022
Lead Product(s) : ENA-001
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable